類器官CHIR-99021
| 參考價 | ￥2112.00 |
- 公司名稱 普邁精醫科技（北京）有限公司
- 品牌其他品牌
- 型號
- 所在地北京市
- 廠商性質代理商
- 更新時間2025/6/26 10:52:18
- 訪問次數 957
| 10mg | 2112.00元 | 10 mg可售 |
聯系方式：林明400-609-0003 查看聯系方式
聯系我們時請說明是化工儀器網上看到的信息，謝謝!
| 供貨周期 | 現貨 |
|---|
類器官CHIR-99021
類器官（Organoids）是指將成體干細胞或多能干細胞在體外三維培養形成的具有一定空間結構的組織類似物。類器官在組織結構、細胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發育生物學、疾病造模、精準醫學、藥物研發、基因和細胞療法、感染和免疫以及再生醫學等生物醫學的多個領域展現出*的優勢。
產品介紹DESCRIPTION
| Background | CHIR-99021 is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3]. | ||
| Alias | Laduviglusib; CT99021 | ||
| M. W t | 465.34 | ||
| Formula | C22H18Cl2N8 | ||
| CAS No | 252917-06-9 | ||
| Storage | Powder | -20°C | 3 years |
| 4°C | 2 years C22H18Cl2N8 | ||
| In solvent | -80°C | 6 months | |
| -20°C | 1 month | ||
| Solubility | DMSO | 16.67 mg/mL(35.82 mM) | |
| H2O | < 0.1 mg/mL(insoluble) | ||
BIOLOGICAL ALTIVITY
In Vitro
CHIR-99021 inhibits human GSK-3β with Ki values of 9.8 nM[1]. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[4]. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC50 of 4.9 mm[2].
In Vivo
In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[5].
類器官CHIR-99021
采購中心
化工儀器網